• Home
  • MedDevices AI
  • Johnson & Johnson MedTech and Qure.ai Partner to Transform Early Lung Cancer Detection

Johnson & Johnson MedTech and Qure.ai Partner to Transform Early Lung Cancer Detection

May 10, 2025 – India
Johnson & Johnson MedTech has announced a strategic collaboration with healthcare AI innovator Qure.ai to enhance the early identification of lung cancer cases across India. This partnership, part of the larger Project BreatheEZ initiative, is focused on deploying AI-driven diagnostic tools to detect incidental pulmonary nodules (IPNs) at an earlier, more treatable stage.

Under this initiative, dedicated IPN Detection Clinics will be established across leading hospitals in India, combining advanced imaging technology with Qure.ai’s artificial intelligence solutions. The program will initially cover 10 central medical hubs and expand to include 20 additional spoke facilities, supporting a networked approach to lung cancer screening and follow-up care. The first center under this model has launched at Thangam Cancer Centre in Namakkal, Tamil Nadu.

With India witnessing a rising cancer burden — projected to increase to nearly 30 million disability-adjusted life years (DALYs) by 2025 — there is a growing need for proactive and scalable solutions. Many lung cancer cases in India go undetected until advanced stages, making early diagnosis a critical area of focus.

Through this collaboration, AI will be used to analyze chest X-rays and CT scans, flagging potentially malignant lung nodules that may otherwise be overlooked. The structured implementation of these IPN clinics aims to introduce incidental screening into routine diagnostics, significantly improving the odds of early intervention.

Anuj Virmani, Managing Director for Johnson & Johnson MedTech India, emphasized the importance of this collaboration:

“Lung cancer remains a major health challenge, particularly in areas where access to advanced diagnostic facilities is limited. This partnership with Qure.ai aligns with our mission to bring life-saving technologies closer to underserved regions and to redefine how early detection can change patient outcomes.”

The partnership represents a step forward in integrating cutting-edge AI with medical practice, setting a new standard for lung cancer care in India and potentially serving as a model for other regions facing similar healthcare gaps.

Releated Posts

Can Zimmer Biomet’s $177 Million AI-Driven Acquisition of Monogram Technologies Redefine the Future of Autonomous Orthopedic Surgery by 2027?

Key Highlights Strategic Acquisition Enhances Zimmer Biomet’s Robotics LeadershipZimmer Biomet’s acquisition of Monogram Technologies, announced in July 2025,…

ByByAnuja SinghAug 5, 2025

How Will Ambience Healthcare’s $243M Series C Propel AI-Driven Clinical Documentation to Transform Healthcare’s Future?

Key Highlights Transforming Clinical Documentation and Workflow with Ambient AIAmbience’s platform listens passively to clinical encounters, generating structured,…

ByByAnuja SinghAug 1, 2025

What Impact Will the Trump Administration’s Private Health Data Initiative Have on Patient Privacy and Healthcare Innovation?

Key Highlights Transforming Access to Health Data Through Private Sector-Led InnovationThe Trump Administration aims to modernize healthcare with…

ByByAnuja SinghAug 1, 2025

Is Mayo Clinic’s NVIDIA Blackwell-Powered DGX SuperPOD the Next Leap in AI-Driven Clinical Innovation?

Key Highlights NVIDIA Blackwell Infrastructure: High-Performance Compute for Healthcare AIThe NVIDIA DGX SuperPOD system delivers state-of-the-art, scalable AI…

ByByAnuja SinghJul 31, 2025
Scroll to Top